Business Description
Iovance Biotherapeutics Inc
NAICS : 325411
SIC : 2834
ISIN : US4622601007
Total Employee Number:
975Description
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.56 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | -0.15 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 0.72 | |||||
Beneish M-Score | -2.71 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 25.5 | |||||
3-Year EPS without NRI Growth Rate | 24.4 | |||||
3-Year FCF Growth Rate | 21.8 | |||||
3-Year Book Growth Rate | -13.9 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 41.87 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.79 | |||||
9-Day RSI | 56.25 | |||||
14-Day RSI | 55.92 | |||||
3-1 Month Momentum % | 9.98 | |||||
6-1 Month Momentum % | 49.96 | |||||
12-1 Month Momentum % | 131.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.6 | |||||
Quick Ratio | 3.15 | |||||
Cash Ratio | 2.42 | |||||
Days Inventory | 111.93 | |||||
Days Sales Outstanding | 92.49 | |||||
Days Payable | 61.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -29.9 | |||||
Shareholder Yield % | -12.63 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 36.71 | |||||
Operating Margin % | -125.36 | |||||
Net Margin % | -123.9 | |||||
EBITDA Margin % | -108.97 | |||||
FCF Margin % | -106.85 | |||||
OCF Margin % | -94.88 | |||||
ROE % | -49.3 | |||||
ROA % | -38.31 | |||||
ROIC % | -73.12 | |||||
3-Year ROIIC % | 0.97 | |||||
ROC (Joel Greenblatt) % | -187.89 | |||||
ROCE % | -45.06 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 5.66 | |||||
PB Ratio | 2.57 | |||||
Price-to-Tangible-Book | 4.1 | |||||
EV-to-EBIT | -4.53 | |||||
EV-to-Forward-EBIT | -5.01 | |||||
EV-to-EBITDA | -5.21 | |||||
EV-to-Forward-EBITDA | -5.01 | |||||
EV-to-Revenue | 5.68 | |||||
EV-to-Forward-Revenue | 4.61 | |||||
EV-to-FCF | -5.32 | |||||
Price-to-GF-Value | 0.22 | |||||
| Price-to-Net-Current-Asset-Value | 7.01 | |||||
| Price-to-Net-Cash | 16.57 | |||||
Earnings Yield (Greenblatt) % | -22.08 | |||||
FCF Yield % | -16.15 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Iovance Biotherapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 245.339 | ||
| EPS (TTM) (€) | -0.817 | ||
| Beta | 2.4277 | ||
| 3-Year Sharpe Ratio | 0.17 | ||
| 3-Year Sortino Ratio | 0.34 | ||
| Volatility % | 90.7 | ||
| 14-Day RSI | 55.92 | ||
| 14-Day ATR (€) | 0.127809 | ||
| 20-Day SMA (€) | 3.493 | ||
| 12-1 Month Momentum % | 131.91 | ||
| 52-Week Range (€) | 1.4306 - 4.7445 | ||
| Shares Outstanding (Mil) | 446.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Iovance Biotherapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Iovance Biotherapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:30 | In 131 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 130 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 16:30 | In 40 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 39 days | ||
| General meeting for 2026 | 2026-06-10 11:00 | 3.44 (+0.00%) | ||
| Guidance call for 2026 | 2026-06-04 13:25 | 3.48 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:30 | 3.40 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 3.40 (+0.00%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-11 09:30 | 4.59 (-0.42%) | ||
| TD Cowen 46th Annual Healthcare Conference Presentation | 2026-03-02 09:50 | 3.16 (+0.00%) |
Show
Entries
Iovance Biotherapeutics Inc Frequently Asked Questions
What is Iovance Biotherapeutics Inc(FRA:2LB)'s stock price today?
The current price of FRA:2LB is €3.65. The 52 week high of FRA:2LB is €4.74 and 52 week low is €1.43.
When is next earnings date of Iovance Biotherapeutics Inc(FRA:2LB)?
The next earnings date of Iovance Biotherapeutics Inc(FRA:2LB) is 2026-08-07 Est..
Does Iovance Biotherapeutics Inc(FRA:2LB) pay dividends? If so, how much?
Iovance Biotherapeutics Inc(FRA:2LB) does not pay dividend.
Press Release
Articles on Iovance Biotherapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers